Cardiovascular and metabolic diseases remain the leading cause of morbidity and mortality worldwide. Endothelial dysfunction is a key player in the initiation and progression of cardiovascular and metabolic diseases. Current evidence suggests that the anti-diabetic drug metformin improves insulin resistance and protects against endothelial dysfunction in the vasculature. Hereby, we provide a timely review on the protective effects and molecular mechanisms of metformin in preventing endothelial dysfunction and cardiovascular and metabolic diseases.
Introduction
Cardiovascular disease (CVD) is the largest cause of morbidity and mortality in modern societies (Fang, Little, & Xu, 2017; Writing Group, et al., 2016) . The major underlying pathology of CVD is atherosclerosis Little, Osman, & O'Brien, 2008; Ross, 1986; Tabas, Williams, & Boren, 2007) . Atherosclerosis is accelerated by the diabetic milieu but the mechanisms of this response are unclear. The impact of drugs which reverse the diabetic state on preventing atherosclerosis and CVD is also controversial (Nigro, Osman, Dart, & Little, 2006; Yang et al., 2010) . The phenomena of endothelial dysfunction (ED) is closely associated with atherosclerosis. In this context, it is important to have a full understanding of the action of drugs which treat the diabetic state and impact on ED for a full appreciation of their potential role in reducing the development and progression of atherosclerosis and hence CVD.
There are many risk factors for CVD most prominently hypertension, hyperglycaemia and hyperlipidaemia which are modifiable by medical treatment. Risk factors are not of concern in their own role but for their role in accelerating the onset or rate of development of atherosclerosis. CVD in diabetes is traditionally divided into the microvascular diseases of small vessels and the macrovascular disease of larger vessels where hyperglycaemia is the cause of the former and it is closely associated with the latter.
Type 2 diabetes is now recognised as an important risk factor for CVD and in patients with diabetes but without a previous cardiovascular event Type 2 diabetes carries a similar risk of a future event to a subject without diabetes who has had a previous event (Haffner, 1997) . The principal metabolic abnormalities of diabetes are insulin resistance, pancreatic beta cell failure and abnormalities of the incretin system where early Type 2 diabetes is characterized by insulin resistance and rising plasma insulin (relative insulin deficiency) and in the later stages beta cell failure leads to an absolute deficiency of insulin and hyperglycaemia. Incretins impact on these two parameters and can modify the progression of disease and also serve as therapeutic targets (Cernea, 2011) .
To be truly efficacious, lowering of risk factors for CVD must have effects on lowering cardiovascular events and increase life expectancy. Medical treatments are often assessed for their acute or short-term effects on risk factors but it is the ultimate outcomes on CVD that are important. Therapeutic agents that are highly effective in reducing risk factors but this may not always be sufficient to reduce the incidence of CVD. The action on risk factors may be counteracted by their deleterious effects on the cardiovascular system such as occurred for COX inhibitors (Fanelli, Ghisi, Aprile, & Lapi, 2017) . Therefore, preferably agents should have range of effects, known as pleiotropic effects directly on the cardiovascular system so that these effects can work in tandem with the risk factor benefit to get an overall reduction in CVD and mortality.
In Type 2 diabetes, it has been extremely difficult to discover agents which can reduce hyperglycaemia and reduce cardiovascular events safely. Indeed, most agents for the treatment of diabetes have not attained these criteria of efficacy and safety. One old agent which had a mixed early therapeutic history is the biguanide, metformin. Metformin has recently risen to the top of the relevant therapeutic armamentarium tree to become the first line medical therapy for the treatment of the hyperglycaemia accompanying Type 2 diabetes (Gray, McGuire, Cohen, & Little, 2017; Stumvoll, Nurjhan, Perriello, Dailey, & Gerich, 1995) . As mentioned above, ED is thought to accelerate the development and progression of atherosclerosis and accordingly targeting and reducing ED is hypothesized to reduce CVD. The overall effect of metformin appears to be a reduction in cardiovascular events but the topic is of some debate (UK Prospective Diabetes Study (UKPDS) Group, 1998) . Understanding the effects of metformin on ED would advance our understanding of the full therapeutic potential of metformin. The effects of metformin, as other risk factor addressing agents, arise from its primary effect on the risk factors (insulin resistance and hyperglycaemia) and its associated direct effects on the vasculature, indeed the endothelium. In this review, we address the use of metformin in diabetes and associated vascular complications, and analyse the effects of metformin on the endothelium due to its anti-hyperglycaemic and vasculoprotective actions. In these days of personalized medicine, a deep understanding of effects of therapeutic agents may point to populations in which the balance of unwanted and favourable effects is tipped in the desired direction and the use of drugs can be optimised. Here we analyse the actions of metformin with a view to seeking optimum patient outcomes for people treated with this ubiquitous agent.
Endothelial function and dysfunction
The endothelium is a single layer of cells which separates all tissues from circulating blood (Chistiakov, Revin, Sobenin, Orekhov, & Bobryshev, 2015; Minami & Aird, 2005) . Intact endothelium acts in an autocrine, paracrine and endocrine manner and secretes a number of bioactive mediators that affect vascular tone (Muniyappa & Sowers, 2013) . A seminal experiment by Robert Furchgott and colleagues (Furchgott & Zawadzki, 1980) demonstrated that removal of endothelium from isolated arteries prevents the ex vivo vasodilatory response to acetylcholine; indeed denuded vessels constrict in response to acetylcholine. Subsequently it was revealed that acetylcholine stimulates the endothelium to release endothelium-derived relaxing factor (EDRF) which was later characterized as the vasoactive gas, nitric oxide (NO) (Ignarro, Buga, Wood, Byrns, & Chaudhuri, 1987) . Healthy endothelium maintains a low level of oxidative stress and a relaxed vascular tone by releasing several vasoactive mediators. Major vasodilators released by endothelial cells include NO, prostacyclin I2 (PGI2) endothelium derived hyperpolarizing factor (EDHF), bradykinin, histamine, serotonin, substance P while the key secreted vasoconstrictors include endothelin-1 (ET-1), angiotensin II (ANG-II), thromboxane A2, prostacyclin H2 and reactive oxygen species (ROS) (Endemann & Schiffrin, 2004; Just, Whitten, & Arendshorst, 2008; Lai & Kan, 2015; Moncada, Gryglewski, Bunting, & Vane, 1976; R MoJ Palmer, Ferrige, & Moncada, 1987; Yanagisawa et al., 1988) . The delicate balance between this plethora of vasodilators and vasoconstrictors and pro-and anti-coagulation factors is crucial for physiological functioning of the endothelium and an imbalanced production of these molecules leads to failed vascular auto regulation and influences the structural and functional integrity of the endothelium with pathophysiological consequences (Ghosh, Gao, Thakur, Siu, & Lai, 2017) . (See Table 1 .)
Endothelial dysfunction
The functional integrity of endothelium is important to vascular health. Imbalance between vasodilators and vasoconstrictors as well as chronic disturbances in mechanical shear stress caused by dyslipidaemia, hypertension and diabetes leads to endothelial dysfunction. Endothelial dysfunction is not only an initiator but also could be an important contributor to the progression of CVD (Barton & Haudenschild, 2001; Endemann & Schiffrin, 2004; Félétou & Vanhoutte, 2006a) . Endothelial dysfunction is characterized and defined by one or more of following features: reduced production and bioavailability of NO, impaired endothelium dependent vasorelaxation, impaired fibrinolytic ability, hemodynamic dysregulation, enhanced expression of adhesion molecules and inflammatory genes, increased generation of ROS and enhanced permeability of vascular endothelium Gimbrone & García-Cardeña, 2016; Sena, Pereira, & Seiça, 2013a , 2013b . In disease states the endothelium undergoes functional and structural alterations and loses its CVD protective role (Versari, Daghini, Virdis, Ghiadoni, & Taddei, 2009 ). Several studies have linked endothelial dysfunction and resultant atherosclerosis to insulin resistant states, such as obesity and diabetes (Bakker, Eringa, Sipkema, & van Hinsbergh, 2009; Table 2 .)
Regulation of vascular tone
The endothelium regulates vascular tone by producing and releasing NO, and prostacyclin and by hyperpolarising vascular smooth muscle cells (VSMCs). NO is the major vasodilator synthesized by endothelial nitric oxide synthase (eNOS or NOS3) (Nishida et al., 1992) . NO is synthesized from the oxidation of L-Arginine (Richard MJ Palmer, Ashton, & Moncada, 1988) , in a twostep process catalysed by eNOS through the generation of N-hydroxyl-L arginine. eNOS is constitutively expressed in endothelial cells, closely associated with caveolae where it binds caveolin-1 that restricts its activity (Palmer et al., 1987) . Other factors that influence the continuous synthesis of NO by endothelial cells include plasma constituents (thrombin, sphingosine1-phosphate), autacoids (bradykinin, histamine, prostaglandin), platelet products (adenosine phosphate, serotonin), neurohumoral mediators such as acetylcholine and circulating hormones (catecholamines, vasopressin and aldosterone) (Michel & Vanhoutte, 2010) . Furthermore, mechanical forces regulate eNOS gene expression differentially in areas of disturbed flow versus steady laminar flow. Endothelial cells exposed to laminar flow possess enhanced NO forming capacity (Chiu & Chien, 2011) . Once produced, NO readily diffuses to VSMCs and activates soluble guanylate cyclase system which in turn results in increased levels of cyclic guanosine-3′, 5 mono phosphate (cGMP) and relaxation of VSMC (Rapoport & Murad, 1983) . NO also exerts its effects by reversible modification of proteins by adding NO group at cysthiol forming S-nitrosylated proteins (Stamler et al., 1992) . S-Nitrosylation of proteins modulates many important physiological processes in the cardiovascular system including cell proliferation, apoptosis, ion channel activity, exocytosis, blood flow and systemic oxygen delivery. Apart from being a key vasodilator, NO counteracts platelet aggregation, VSMC proliferation and leukocyte 
Vasodilators
• NO (Ignarro et al., 1987; Palmer et al., 1987) • PGI2 (Egan & FitzGerald, 2006; Moncada et al., 1976) • Bradykinin (Drexler, 1998) , • EDHF (Davignon & Ganz, 2004; Félétou & Vanhoutte, 2006b; Garland, Hiley, & Dora, 2011 
• ET-1 (Yanagisawa et al., 1988) ,
• PAI-1 (Kruithof, Nicolosa, & Bachmann, 1987) ,
• Transforming growth factor -beta (TGFβ) Promoters
• Platelet derived growth factor • fibroblast growth factor • insulin like growth factor • ET-1 Table 2 Factors mediating and impacting on endothelial dysfunction.
Notorious stimuli Molecular changes leading to endothelial dysfunction

Hypercholesterolemia
• Reduced endothelium dependent vasorelaxation (Sena et al., 2008) .
• Up regulation of NOX and ROS reducing the bioavailability of NO, eNOS uncoupling (Böger et al., 2004; Speer et al., 2014) . Insulin resistance
• Increased production of ROS by NOX(J. Du, Fan, Mai, & Li, 2013) • over-expression of PKCβ and induction of ET-1 expression in endothelium (Tabit et al., 2012) • increased insulin receptor substrate • Phosphorylation at Ser 307 (Nemoto, Kobayashi, Taguchi, Matsumoto, & Kamata, 2011) • Up regulation of transcription factor forkhead boxO-1 FOXO-1 (Karki et al., 2015) . Diabetes
• Induced endothelial dysfunction • Advanced end glycation product (AGE)
• ROS (Paneni, Beckman, Creager, & Cosentino, 2013) . Pro inflammatory factors
• Overexpression of TNFα and IL-1 which promotes leukocyte adherence and migration (Barton, 2013) • Inflammatory cytokines induced endothelial cells express VCAM, ICAM, MCP1, IL6, P-selectin and E -selectin and exacerbate the ED (Blake & Ridker, 2001 ) • C-reactive protein directly affects NO bioavailability acting through lectin like oxidized LDL receptor-1 which plays pivotal role in oxLDL-induced ED in endothelial cells (L. Li, Roumeliotis, Sawamura, & Renier, 2004) . Hypertension
• Reduced NO availability in response to endothelium dependent stimuli in hypertension is attributed to higher levels of ADMA (Sasser, Cunningham, & Baylis, 2014) . Aging
• Aging results in diminished production of NO due ○ Increased activity of arginase competing with eNOS for common substrate arginine (Santhanam et al., 2007) ○ Reduced expression and activity of eNOS (Lesniewski et al., 2011) ○ Decrease release of prostanide (Gano et al., 2014) ○ Increase release of ET-1.
Hemodynamic forces
• Low sheer stress modulates gene expression through mechanoreception and mechanotransduction resulting in altered atherogenic endothelial phenoytype and formation of atherosclerotic plaque (Pahakis, Kosky, Dull, & Tarbell, 2007) • Suppression of NO and prostacyclin, augmentation of ET-1, lipid uptake and its catabolism induce plaque inflammation and oxidation in endothelial cells (White et al., 2011 ) Environmental factors
• Processes in smoking induce atherogenesis, endothelial dysfunction and damage,
• Induction of inflammation, increase in oxidation of proatherogenic lipids and shift towards procoagulant state in circulation (Messner & Bernhard, 2014 ) Psychological stress
• Sleep deprivation decrease eNOS and cGMP levels indicating damaged eNOS/NO/cGMP/pathway (Jiang et al., 2017) . Diet
• High salt intake results in blunted endothelium dependent vasodilation (Beyer et al., 2014) . Oxidative stress (H 2 O 2 )
• Super oxide anions scavenge NO and form peroxynitrate resulting in reduced bioavailability of NO (Montezano & Touyz, 2012) .
• ROS cause S-glutathionylation of eNOS and render it inactive (Y. Zhang, Janssens, Wingler, Schmidt, & Moens, 2011) Infectious agents (e.g., bacterial endotoxins, viruses)
• Infectious agents such as hepatitis A virus, herpes simplex virus-1, cytomegalovirus and bacteria (Helicobactor pylori,and Chlamydia pneumonia) are reported to be associated with coronary artery disease Life style (sedentary)
• Cardiac patients with lower physical activity levels exhibits ED manifested by reduced flow mediated vasodilation (Luk et al., 2012) adhesion to the endothelium (de Graaf et al., 1992; Cornwell, Arnold, Boerth, & Lincoln, 1994) . The endothelium also mediates the hyperpolarization of VSMCs by releasing EDHF and directly by intercellular communication through gap junctions. NO and other vasodilators act cooperatively and oppose the action of vasoconstrictors this maintaining the normal arterial patency.
Endothelial transmigration by blood borne cells
Inflammation is a key player in both the development and acute activation of vascular cells (Libby, Ridker, & Hansson, 2011) . Under physiological conditions, the endothelium resists attachment of leukocytes to its surface (Libby et al., 2011) . NO maintains the endothelium in a quiescent, anti-inflammatory state and prevents leukocyte adhesion (Widlansky, Gokce, Keaney, & Vita, 2003) . However, the endothelium shows up regulated expression adhesion molecules such as vascular adhesion molecule 1 (VCAM-1) and intracellular adhesion molecule 1 (ICAM-1) (Libby, Ridker, & Maseri, 2002) in CVD risk factors, such as dyslipidaemia, hypertension and increased proinflammatory mediators. Consequently, the endothelium is rendered adhesive for circulating leukocytes, thereby initiating an intriguing multistep process involving capturing, rolling, arrest, crawling (to the site of injury) and transmigration through the barrier formed by endothelial cell monolayers (Vestweber, 2015) . The activated endothelium also expresses chemotactic factors such as monocyte chemoattractant protein-1 (MCP-1) and proinflammatory cytokines such as macrophage colony-stimulating factor, and tumour necrosis factor-alpha (TNFα) (Libby et al., 2002) . Expression of these factors in the endothelium contributes to the development of inflammation in the arterial wall and promotes atherogenesis.
The phenomenon of endothelial cell senescence
The phenomenon of cellular senescence is characterized by cell cycle arrest and pro-inflammatory gene expression (Rodier & Campisi, 2011) . Endothelial senescence occurs in vivo and is a major contributor to vascular aging (Erusalimsky, 2009; Wang & Bennett, 2012) . Cellular senescence is driven by many factors including, high glucose, ROS, inflammatory cytokines, telomere dysfunction, and ionizing radiation (Kojima, Kunimoto, Inoue, & Nakajima, 2012; Minamino et al., 2002; Rogers, Zhang, Azhar, Luo, & Wei, 2013; Valenzuela et al., 1997; Vasto et al., 2007) . Substantial evidence indicates that hyperglycaemia-induced ROS formation and reduced bioavailability of NO promotes DNA damage, shortening of telomeres, genomic instability and growth arrest in endothelial cells, thus resulting in premature endothelial cell senescence (Hoffmann et al., 2001; Matsui-Hirai et al., 2011; Ota et al., 2008; Yokoi et al., 2006) . These phenotypically altered endothelial cells are pro-inflammatory, pro-thrombotic and pro-atherosclerotic with diminished antigenic and regenerative properties (Erusalimsky, 2009; Testa & Ceriello, 2007) and augmented diabetes associated CVD.
Endothelial cell apoptosis in the functioning of the endothelium
Endothelial cell apoptosis is a crucial process for development of atherosclerosis (Peng et al., 2014) . The hyperglycaemia of diabetes can induce apoptosis by one or more of the following mechanisms: increased intracellular Ca 2+ , increased oxidative stress, mitochondrial dysfunction, changed intracellular fatty acid metabolism, impaired phosphorylation of protein kinase Akt and activation of mitogen activated protein kinase (Isoda et al., 2006) .
Hyperglycaemia increases Bax protein expression, but does not affect that of Bcl-2. Elevated Bax/Bcl-2 ratio activates the cleavage of procaspase3 into active caspase-3 and triggers apoptosis in Human Umbilical Vein Endothelial Cells (HUVECS) (Yang et al., 2008) . Intracellular ROS generation is an important cause of apoptotic cell death and is also involved in the development of diabetic vascular disease (T. Yu, Sheu, Robotham, & Yoon, 2008) . Hyperglycaemia induced intracellular ROS activate JNK and p38 pathway and triggered subsequent apoptosis in HUVECS (Ho et al., 2006) . ROS accumulation in mitochondria is a trigger for the intrinsic death pathway, subsequently leading to apoptosis (Goyeneche, Harmon, & Telleria, 2006) . There are many pathways involved in activating endothelial cell apoptosis but a common mechanism causing endothelial dysfunction and endothelial apoptosis is oxidative stress (Van den Oever, Raterman, Nurmohamed, & Simsek, 2010).
Biochemical mechanisms associated with endothelial dysfunction in diabetes
Insulin resistance and endothelial cell dysfunction
In the diabetic milieu, the metabolic disturbances of insulin resistance, hyperglycaemia and excessive circulating free fatty acids induces oxidative stress, low grade inflammation, platelet hyperactivity and endothelial dysfunction in the vascular tissues (Sena et al., 2013a (Sena et al., , 2013b . Insulin resistance is linked with lipotoxicity, glucotoxicity and inflammation, which initiates and accelerates atherogenesis and vascular disease (Kamato et al., 2014; Little et al., 2008; Nigro et al., 2006; Ouchi, Parker, Lugus, & Walsh, 2011; Yang et al., 2010) . A decade ago we speculated that insulin resistance was due to the action of an unknown lipophilic metabolite which attenuated insulin signalling and this speculation remains valid to this day (Nigro et al., 2006) . Insulin signal transduction occurs through two major and ubiquitous signalling pathways. PI3K is involved in mediating the metabolic and hemodynamic effects while the Ras-Raf-mitogen-activated-protein kinase (MAPK) pathway mediates gene expression, cell growth and differentiation (Avruch, 1998; Nigro et al., 2006) . Under normal physiological conditions, insulin activates the PI3K pathway, which phosphorylates eNOS at Serine 1177 site, thereby enhancing NO synthesis by endothelial cells (Dimmeler et al., 1999) . In insulin resistant states, this pathway is impaired and NO production is diminished. Alternatively, the MAPK pathway evokes the synthesis of inflammatory markers PAI-1, ICAM-1, VCAM-1, and E-selectin resulting in endothelial dysfunction (Montagnani et al., 2002; Muniyappa & Sowers, 2013 ). An imbalance between the PI3K and MAPK pathways provides a strong link between insulin resistance and endothelial dysfunction (Hsueh & Quiñones, 2003; Kim, Montagnani, Koh, & Quon, 2006) . This relationship is accelerated by selective inhibition of insulin signalling to eNOS via PI3K, whereas MAPK signalling to ET-1 is unaltered or increased (Jiang et al., 1999) . Endothelial dysfunction due to impaired insulin signalling reduces agonist-induced vasodilation and the vascular wall becomes more susceptible to atherosclerosis (Maeno et al., 2012; Rask-Madsen et al., 2010) . Furthermore insulin resistance also stimulates VSMC proliferation, migration, and causes excessive release of free fatty acids from adipose tissue, which elicits pathogenic gene expression through activation of protein kinase C (PKC) and raised oxidative stress (Hajer, van Haeften, & Visseren, 2008) .
Hyperglycaemia and endothelial dysfunction
Hyperglycaemia is an important factor in endothelial dysfunction and several theories have been proposed to explain its adverse effects on the endothelium. These include the advanced glycation end product hypothesis, hexosamine hypothesis, aldose reductase hypothesis, the hyperperfusion hypothesis, PKC hypothesis and the oxidative stress hypothesis (Giacco & Brownlee, 2010) . These hypotheses have overlapping points that potentiate each other but oxidative stress is most likely the common disturbance of hyperglycaemia (Brownlee, 2001 ; Van den Oever et al., 2010) . ROS reduces glucose metabolism via glycolysis, alternatively, there is increased flux through the hexosamine and polyol pathways. Hyperglycaemia induced oxidative stress, causes DNA damage and activates nuclear poly (ADP-ribose) polymerase which results in enhanced production of polymers of ADP-ribose (PAR). Subsequently, these polymers of ADP-ribose cause modification and inactivation of glyceraldehyde phosphate dehydrogenase (GAPDH) (Du et al., 2003; Giacco & Brownlee, 2010) . Ultimately, the accumulation of upstream glycolytic intermediates glycraldehyde-3-phosphate and dihydroxy acetone phosphate (DHAP), which can be converted to diacylglycerol, activates classical and novel PKC pathways (Way, Katai, & King, 2001) . There are at least 11 PKC isoforms and PKCβ is most frequently the activated form in vascular cells. The pathogenic consequences of PKC activation include dysregulated blood flow due to diminished eNOS activity and increased ET-1 synthesis and (Chen, Apostolova, Cherian, & Chakrabarti, 2000) , impaired vascular permeability in VSMC due to induction of vascular endothelial growth factor (Williams, Gallacher, Patel, & Orme, 1997) , thickening of basement membranes through TGF-β mediated increased synthesis of collagen IV and fibronectin, increased plasminogen activator inhibitor -1 (PAI-1) expression which impairs fibrinolysis and activation of NADPH oxidase as well as increased expression of superoxide producing uncoupled eNOS thus further increasing oxidative stress.
Glucotoxicity induces a low grade pro-inflammatory state due to activation of transcription factors such as nuclear factor kappa B (NF-κB), a key regulator of pro-atherosclerotic and pro-inflammatory gene targets in VSMC, endothelial cells and macrophages (Avogaro, de Kreutzenberg, & Fadini, 2008; Brownlee, 2005; Creager, Lüscher, Cosentino, & Beckman, 2003; Little, Chait, & Bobik, 2011) . Endothelial cells exposed to hyperglycaemic culture media show enhanced NF-κB activation with reduced NO production, leukocyte recruitment and inflammatory gene expression (Ding, Vaziri, Coulson, Kamanna, & Roh, 2000; Du et al., 2001; Esposito et al., 2001; Luppi, Cifarelli, Tse, Piganelli, & Trucco, 2008; Piconi et al., 2004; Piga, Naito, Kokura, Handa, & Yoshikawa, 2007) .
Advanced glycation end products (AGEs) and endothelial dysfunction
Hyperglycaemia promotes non-enzymatic glycation of intracellular and extracellular proteins, culminating in the formation of AGEs which subsequently accumulate in the vascular wall and decrease NO activity and eNOS expression and increase the expression of ET-1 (Avogaro et al., 2008; Ballinger et al., 2005; Quehenberger et al., 2000; Soldatos, Cooper, & Jandeleit-Dahm, 2005) . Modification of extracellular proteins, e.g. laminin and collagen, increase fluid filtration and decreases vessel elasticity (Huijberts et al., 1993) . AGE modification of intracellular and extracellular proteins affects their functions and receptor binding properties. Binding of AGEs to their receptors (RAGE) increases intracellular enzymatic superoxide production (Schmidt, Du Yan, Wautier, & Stern, 1999; Wautier et al., 2001) . Excessive production of ROS by AGEs activates NF-κB and TNFα, which further enhances the production of superoxide (Kim, Lee, Park, & Yoo, 2010; Roberge et al., 2014; Ungvari et al., 2007) .
Under hyperglycaemic conditions, a number of biochemically active substances such as 3-deoxyglucosone, amadori products, diacylglycerol, methylglyoxal, ROS, AGE and nitrosylated species are produced which contribute to and promote diabetes-associated endothelial dysfunction (Sena et al., 2012) . Thus, oxidative stress seems to be a common alteration triggered by hyperglycaemia adjoined by hyperinsulinemia, hyperlipidaemia and insulin resistance (Potenza, Gagliardi, Nacci, Carratu, & Montagnani, 2009 ).
Oxidative stress and endothelial dysfunction
Within the vessel wall, oxygen derived radicals like superoxide anions are generated by a variety of enzymatic mechanisms. Molecular sources of ROS in the vasculature include enzymes of the respiratory chain, specific NADPH oxidase (NOX) complexes, xanthine oxidase, uncoupled eNOS, cyclooxygenase, lipoxygenase and cytochromeP450 monooxygenase (Cai & Harrison, 2000; Ježek & Hlavatá, 2005 Caterina, 2005; Turrens, 2003) . NOXs are the only enzyme with the primary function of generating ROS (Drummond, Selemidis, Griendling, & Sobey, 2011; Lassègue, San Martín, & Griendling, 2012) . Under normal physiological conditions, the detrimental effects of ROS are counter-balanced by vascular antioxidant enzymes including catalases, superoxide dismutases, glutathione peroxidases, glutathione S-transferases, glucose-6-phosphate dehydrogenases and heme oxygenase (Leopold & Loscalzo, 2009 ). In a state of oxidative imbalance, excessive production of ROS is implicated in the pathogenesis of various diseases including aging, dementia, ischemia-reperfusion injury and atherosclerosis (Madamanchi, Vendrov, & Runge, 2005) . Thus, increased oxidative stress is another important mechanism of endothelial dysfunction in diabetes mellitus and associated conditions.
The biguanide anti-hyperglycaemic agent, metformin
Metformin is an old drug that has been used to treat diabetes for 60 years (Bailey & Turner, 1996; . In recent times, it has evolved to be the first line pharmacological choice for the treatment of Type 2 diabetes. Metformin is a member of the biguanide family of drugs, which include phenformin and buformin. Phenformin and buformin, showed a very high risk of severe lactic acidosis events, whilst the risk of lactic acidosis with metformin remains low and was probably overstated in its earlier use.
As for many drugs, the use of metformin has occurred without a full understanding of its mechanism of action, but recent investigations provide expanding knowledge in this area. Metformin exerts its antihyperglycaemic effect in several ways. Metformin primarily lowers glucose levels in blood by increasing insulin sensitivity and thus increasing uptake of glucose by muscle cells and by reducing production in the liver. New studies investigated the effect of metformin on the incretin and GLP1 systems (Zhao et al., 2015) , showing intestinal AMPK pathways increasing secretion of GLP1 and related peptides (Defronzo et al., 2016) . The gut directed action is an important component of the anti-hyperglycaemic action of metformin.
In skeletal muscle, metformin improves the uptake of glucose into cells via activation of the solute carriers (SLC2A4) and GLUT4 deployment. Inhibition of complex 1, in the mitochondrial respiratory chain, decreases the ATP/AMP ratio (leading to increased activation of AMPK). This action inhibits the production of glucose-6-phosphatase dehydrogenase (G6PDH) (mimicking the normal feedback mechanism and reduces the production of glucose) and phosphoenolpyruvate carboxykinase (PEPCK). It is the interference with glycogenolysis and glycolysis by metformin that leads to the production of lactic acid, where tissues are hypoperfused or hypoxic and the rare potential development of lactic acidosis (Salpeter, Greyber, Pasternak, & Salpeter, 2003) .
Metformin raises the tissue concentration of hydrogen sulphide (H 2 S), which is an atheroprotective gasotransmitter (Hamidi Shishavan et al., 2017; Xu, Liu, & Liu, 2014) . H 2 S functions as a vasculoprotective factor by sulfhydrating potassium channels and acting as an EDHF (Félétou, 2011) . EDHF-mediated responses are modified in various pathological conditions (hypertension, atherosclerosis, hypercholesterolemia, heart failure, ischemia-reperfusion, angioplasty, eclampsia, diabetes, sepsis) and with aging (Feletou & Vanhoutte, 2004 . This could be the mechanism for enhanced acetylcholine induced relaxation seen when metformin was used (Marfella et al., 2010) .
Metformin attenuates fluctuating glucose-induced endothelial dysfunction through enhancing guanosine 5′-triphosphate cyclohydrolase 1 (GTPCH1) mediated eNOS recoupling and inhibiting NADPH oxidase . Endothelial dysfunction, characterized by reduced NO bioavailability, is involved in the initiation and progression of the vascular complications of diabetes (Davignon & Ganz, 2004; Esper et al., 2006) . eNOS is responsible for most of the endothelial NO production. GTPCH1 is a rate limiting enzyme to produce BH4, and if BH4 production falls then NO production is reduced.
Currently, G6PDH appears to be the mitochondrial target of action of metformin. G6PDH is inhibited by the hyperglycaemia-mediated increase in protein kinase A and is the rate limiting step in the pentose phosphate pathway . Reduced G6PD activity reduces NADPH levels, the cells' principal reductant molecule, leading to an increase in oxidative stress. Metformin mediated increase in AMPK, will reduce PKA signalling through phosphorylation of the CREB cycle, reversing hyperglycaemia induced inhibition of G6PDH and reducing oxidative stress (Lee & Yu, 2016; .
Triggle et al. ) identified a number of endothelium-specific micro RNAs as regulators of endothelial function, and linked them to regulation of angiogenesis (cell proliferation, aging and apoptosis) and the development of diabetes-induced endothelial dysfunction and inflammation . High glucose increases the levels of miR34a in microvascular endothelial cells and this is prevented by metformin . Metformin is therefore thought to have a direct effect on endothelial function through antioxidant effects via regulation of eNOS, improved NO production, inhibition of mitochondrial complex 1, activation of AMPK and inhibition of apoptosis . Regardless of the cell Type, AMPK activation can explain most, if not all of the cellular actions of metformin.
Blood levels of metformin are obviously relevant to the actions of metformin. Importantly, metformin is not metabolised in animals or humans and is eliminated intact via renal mechanisms (He & Wondisford, 2015) . One implication of this metabolic profile is that metformin is less sensitive to metabolic drug interactions and interactions arise related to the uptake and transport mechanisms that move metformin around the body. The maximum dose of metformin orally in humans in most settings is 2.5-3 g per day which equates to approximately 35-42 mg/kg (Davoren, 2014; He & Wondisford, 2015) . This produces a trough steady-state plasma concentration for metformin of between 54 and 4133 ng/ml and is highly dependent on the individual (Christensen et al., 2011; Gong, Goswami, Giacomini, Altman, & Klein, 2012) . The difficulty of recognising therapeutic concentrations of metformin has recently been reviewed (Kajbaf, De Broe, & Lalau, 2016) . In humans metformin concentrations after passage through the liver are usually in the range of 10-40 μM (He and Wondisford, 2015) .
Plasma concentrations of metformin in animal studies are in the range of 10-70 μM (He & Wondisford, 2015; Wilcock & Bailey, 1994) . Doses of metformin used in rat studies are typically in the range of 100 mg/kg, in excess of doses attainable in human in vivo studies (Pournaghi, Sadrkhanlou, Hasanzadeh, & Foroughi, 2012) . Palmitic acid induced endothelial dysfunction in HUVECS was attenuated by metformin at 0.5-1 mM concentrations (Ke et al., 2017) . Metformin has been used for in vitro studies at concentrations up to 10 mM (Dallaglio et al., 2014; Little et al., 2007) which greatly exceeds in vivo concentrations and such studies reveal actions of metformin that may be interesting but are not clinically or therapeutically relevant.
Metformin and endothelial dysfunction
Clinical studies of metformin action on hyperglycaemia and associated insulin resistance have addressed its effects on endothelial dysfunction. In 2001, Mather, Verma, & Anderson (2001) evaluated the effect of metformin on endothelial function in patients with Type 2 diabetes and observed that metformin intake improves insulin resistance and endothelium-dependent vasodilation assessed using forearm plethysmography; endothelium-independent and nitrate-independent vasodilation remained unaffected in these studies. These data indicate that metformin induced insulin sensitivity associates with its vasodilatory effects. Since inflammation is a factor in different phases of atherosclerosis, long-term treatment (4.3 years) with metformin added to insulin therapy attenuates several inflammatory biomarkers of endothelial dysfunction (such as vWF and soluble VCAM-1) in patients with Type 2 diabetes, indicating the potential utility of metformin in reducing cardiovascular morbidity and mortality (de Jager et al., 2014) . Similarly, in 2005, Vitale et al. (2005) examined the effect of metformin (500 mg, b.i.d, 3 months) on endothelial function in 65 patients with metabolic syndrome and observed that metformin treatment improved endothelium-dependent flow-mediated dilatation in the brachial artery and insulin resistance (measured by homeostasis model assessment-insulin resistance or HOMA-IR), indicating that insulin resistance and endothelial dysfunction are interrelated and can be influenced by metformin. Metformin treatment also improves flowmediated dilation in patients with Type 1 diabetes (Pitocco et al., 2013) . The REMOVAL trial in Type 1 diabetes showed no benefit in endothelial dysfunction from glycaemic control, however, it did indicate benefit in cardiovascular risk (Petrie, et al., n.d.) . Other studies (Jensterle et al., 2008; Naka et al., 2011) involving women with polycystic ovary syndrome (PCOS) treated with metformin or rosiglitazone, showed that metformin is as effective as rosiglitazone in improving flow mediated vasodilation, without affecting endothelium-independent relaxation. Metformin treatment is also associated with a decrease in HOMA-IR. Metformin treatment for 3 months improves arterial stiffness and associated endothelial dysfunction as well as reducing carotid intima media thickness in women with PCOS (Agarwal et al., 2010; Kaya et al., 2015) . There are several clinical trials (https://clinicaltrials.gov) addressing the effects of metformin alone (NCT00169624) or in combination with other anti-diabetic drugs in patients with Type 2 diabetes (NCT00169624) and PCOS (NCT01459445). Therefore, metformin monotherapy or in combination with other anti-diabetic strategies represents a useful therapeutic option for targeting the endothelial dysfunction which accompanies hyperglycaemia and insulin resistance. The UKDPS data from the aggregate of all the studies showed there were fewer diabetes-related endpoints , p = .033) in the metformin group (UK Prospective Diabetes Study (UKPDS) Group, 1998) .
Molecular mechanism(s) of metformin actions in improving endothelial dysfunction
Inhibition of inflammatory response and oxidative stress in endothelial cells
An earlier study in 2003 showed that metformin (0.1-2.5 μg/ml) inhibited monocyte adhesion induced by advanced glycation end-products (AGE) by repressing endothelial cell adhesion molecules (Mamputu, Wiernsperger, & Renier, 2003) . This pharmacological effects was also observed by Hattori et al. (Hattori, Suzuki, Hattori, & Kasai, 2006) who showed that metformin (2-10 mM), like the AMPK activator AICAR, inhibits endothelial cell inflammation via AMPK-dependent inhibition of the IKK/IKBα/NF-KB pathway (Fig. 1) . The consequence of metformin treatment is the inhibition of the TNF-α-induced gene expression of VCAM-1, E-selectin, ICAM-1, and MCP1, which contribute to monocyte adhesion to activated endothelial cells. Pro-inflammatory cytokines like VCAM1 and MCP1 are also repressed by corepressor BCL6, and PARP1 suppresses BCL6 expression by binding to intron 1 of BCL6. Metformin (1 mM) up regulates BCL6 expression via AMPK-dependent phosphorylation of PARP1 at ser177 (Gongol et al., 2013) , suggesting that metformin could be a useful agent in preventing monocyte adhesion to endothelial cells. Additional mechanisms of action of metformin include the inhibition of LOX-1 signalling, which is an important mediator in endothelial dysfunction and atherosclerosis (Xu et al., 2013) . By ameliorating oxLDL-induced LOX-1 expression, metformin (20 μM) decreases intracellular oxidative stress (Hung, Chan, Chu, Lin, & Tsai, 2016) . The anti-oxidative function of metformin (10 μM-1 mM) is also related to inhibition of TRAF3IP2 (Valente, Irimpen, Siebenlist, & Chandrasekar, 2014) .
11.2. Improved NO production and endothelium-dependent vasorelaxation eNOS dependent NO production increases endothelium-dependent relaxation. Metformin (60 mg/kg/d) treatment restores endothelial function in the aorta of STZ-treated rats (Type 1 diabetes model) as well as Goto-Kakizaki (GK) rats (Type 2 diabetes model) by increasing NO bioavailability and normalizes endothelium-dependent vasorelaxation (Sena et al., 2011) . In 2006, a landmark study by the Zou group identified that AMPK activation by therapeutically relevant concentrations of metformin (50-500 μM) increased NO production via increasing eNOS phosphorylation and eNOS interaction with HSP90. Of clinical relevance, metformin restored impaired eNOS-HSP90 interaction in endothelial cells exposed to high glucose levels (Davis, Xie, Viollet, & Zou, 2006) . The eNOS activating effect of metformin (250 mg/kg/d) has also been demonstrated in endothelial progenitor cells from STZ-induced diabetic mice . In agreement with these data, metformin (300 mg/kg/d) treatment also increase protein expression of GCH1 (the rate-limiting enzyme in BH4 biosynthesis) in wild type as well as Ins2 (+/Akita) mice and glomerular endothelial cells by slowing down the degradation rate of GCH1, without affecting GCH1 gene expression. This suggests that the upregulation of GCH1 by metformin occurs through a posttranslational mechanism (Kidokoro et al., 2013) . Metformin (300 mg/kg/d) mediated upregulation of GCH1 protein expression (but not gene expression) is also seen in streptozotocin-induced diabetic mice and high glucose treated human endothelial cells by preventing proteasome-mediated GCH1 degradation (Wang, Xu, Song, Viollet, & Zou, 2009 ). Since metformin induced GCH1 upregulation can be reversed by a dominant negative mutant of AMPK (Wang et al., 2009) , it is highly possible that AMPK is involved in the GCH1 upregulatory effects of metformin. Metformin (100 mg/kg/d) also increases NO bioavailability by inhibiting ER stress and ROS generation via AMPK and PPARδ pathways (Cheang et al., 2014) . These protective actions contribute to the improved endothelium-dependent relaxation in mice under diabetic and obese conditions (Cheang et al., 2014) .
Inhibition of endothelial senescence and apoptosis
The senescence and apoptosis of endothelial cells is an important contributor to endothelial dysfunction by increasing pro-inflammatory cytokine expression and cell cycle arrest. High glucose induces endothelial cell senescence by repressing SIRT1 expression. Metformin (50 μM) improves endothelial senescence in high glucose treated endothelial cells by increasing SIRT1 expression and activity, thereby repressing high glucose induced endothelial cell aging and apoptosis (Arunachalam, Samuel, Marei, Ding, & Triggle, 2014) . In addition, metformin (50 μM) also repressed senescent "memory" induced by high glucose through increasing SIRT1 activity (Zhang et al., 2015) . Under diabetic conditions, excessive high level of blood glucose causes endothelial injury and apoptosis. In this regard, metformin (100 μM) ameliorates high glucose induced cell death in endothelial cells from multiple origins by suppressing mitochondrial permeability transition (Detaille et al., 2005) .
Improved vascular integrity
Increased vascular permeability causes endothelial leakage and the extravasation of monocytes. Metformin (0.1-1 mM) decreases vascular permeability in brain endothelial cells via AMPK, suggesting the utility of metformin in preventing the initiating event of endothelial dysfunction in endothelial cells (Takata et al., 2013) . Endothelial glycocalyx is an important Type of matrix structure that prevents vascular permeability. Metformin (0.33 mg/ml) treatment of db/db mice leads to improved glycocalyx barrier function and prevents edema in the heart and kidney Fig. 1 . Role of metformin in endothelial dysfunction. Metformin improves endothelial dysfunction via the following aspects: (1) inhibiting leukocyte adhesion; (2) increase nitric oxide production and inhibiting eNOS uncoupling; (3) inhibiting vascular aging; (4) prevent endothelial cell injury and apoptosis. The pharmacological effects of metformin were exerted through LKB1/AMPK and other targets. Abbreviations: NF-kB, nuclear factor kappa B; ICAM1, intracellular adhesion molecule 1; VCAM1, vascular adhesion molecule 1; MCP1, monocyte chemo attractant protein 1; Bcl6, B-cell lymphoma 6; PAPP1-p, phosphorylation of poly-ADP-ribose polymerase 1; LOX-1, lectin-like oxidized LDL receptor 1; TRAF3IP2, TRAF3 interacting protein 2; NOX, NADPH oxidase; ROS, reactive oxygen species; Mn-SOD, manganese superoxide dismutase; AGE, advanced glycation end-products; eNOS, endothelial nitric oxide synthase; eNOS-p, phosphorylation of eNOS; HSP90, heat shock protein 90; GCH1, GTP cyclohydrolase I; BH4, tetrahydrobiopterin; PPARδ, peroxisome proliferator-activated receptor δ; PGC1α, PPARgamma coactivator 1alpha; ER, endoplasmic reticulum; mTOR, the mammalian target of rapamycin; Sirt1, Sirtuin 1, mPTP, mitochondrial permeability transition pore.
of the mice (Eskens, Zuurbier, van Haare, Vink, & van Teeffelen, 2013) . Metformin (5 mM for in vitro studies, and 400 mg/kg bid for in vivo studies) decreases permeability in endothelial cells stimulated with high glucose and LPS as well as improving lung barrier integrity in both STZ-induced diabetic and db/db mice models; the mechanism is linked to the activation of the LKB1/AMPK pathway (Yang et al., 2017) .
12. New mechanistic insights into the actions of metformin in cardiovascular and other systems
Epigenetic effects of metformin
Emerging evidence has shown that metformin also has epigenetic functions, which has been reviewed elsewhere recently (Bridgeman, Ellison, Melton, Newsholme, & Mamotte, 2018) . Metformin can influence the activation of multiple epigenetic modifiers, mostly via AMPK, since AMPK can phosphorylate multiple substrates, including histone acetyltransferases, class II histone deacetylases (HDACs) and DNA/histone methyltransferases, thus leading to their inhibition; Metformin can also increase SIRT1 activity and protect against high glucose induced "memory" in endothelial cells (Zhang et al., 2015) . In addition, Metformin delays endothelial senescence via AMPK-dependent upregulation of histone methyltransferse DOTL1, thereby increasing binding of H3K79me3 to SIRT3 gene promoter (Karnewar et al., 2018) . These epigenetic effects of metformin underlies its broad regulatory effects on gene expression. More recently, Chen et al. (Chen et al., 2018) have shown that metformin (1-50 μM) has anti-inflammatory effects by reducing the expression IP-10, MCP-1 and NF-kB phosphorylation in LPS-stimulated THP1 cells. Furthermore, the authors observed that metformin reduces IL-10 expression by reducing the binding of global acetylated histones H3 and H4 to IP-10 gene promoter in LPS-stimulated THP-1 cell. In another study by Tang et al. (2018) , Metformin (2.5-10 mM) has been reported to inhibit the proliferation and migration, and promotes apoptosis of ovarian cancer cells by increasing AMPK phosphorylation, and reducing PRC2 components expression and associated H3K27 trimethylation. Moreover, EZH2 overexpression abrogated the anti-cancer effect of metformin. This epigenetic effect of metformin is AMPK-dependent, since AMPK inhibition by Compound C, abolishes the effect of metformin on reducing H3K27me3. In light of recently evidence showing atherogenic role of PRC2 component EZH2 (Lv et al., 2016; Xiaoling et al., 2016) and associated H3K27me3 (Xu et al., 2018) in atherosclerosis, it will be of interest whether metformin reduces PCR2 components and activity in endothelial cells. Further research into this area will reveal a novel mode of action for metformin and raises the possibility that metformin may be exploited as epigenetic drug that could affect atherogenic processes, including endothelial dysfunction.
Metformin on autophagy
Decreased AMPK activity and associated defective autophagy is associated with atherosclerosis. After incubating with in high glucose (25 mM) and subsequently with 0.4 mM palmitate, human aortic endothelial cells displayed decreased AMPK activation, impaired autophagy and are prone to apoptosis and enhanced monocyte adhesion to endothelial cells. These effects are reversed by autophagy activator rapamycin and AMPK activators (AICAR, A769662, and phenformin). This study suggests that AMPK activation could prevent glucose and palmitate induced AMPK uncoupling from autophagy in endothelial cells (Weikel, Cacicedo, Ruderman, & Ido, 2015) . In vivo, administration of metformin (250 mg/kg/d) in ApoE −/− mice lead to significant reduction and stabilization of atherosclerotic plaques, associated with increased content of smooth muscle cells, and collagen, as well as reduced content of macrophages (Michiels, Apers, De Meyer, & Martinet, 2016) . Metformin treatment also induce autophagy by reducing SQSTM1/p62 and increasing GFP-LC3 cleavage into free GFP in GFP-LC3 transgenic mice. In cultured endothelial cells, 2 days treatment of metformin (10 mM) attenuates monocyte adhesion to TNFa-activated endothelial cells via repressing ICAM1 and VCAM1. However, metformin mediated protective effects was reversed by autophagy inhibition using Atg7 siRNA-mediated depletion (Michiels et al., 2016) . It remains to be clarified whether AMPK is involved in metformin mediated autophagy induction in endothelial cells.
Metformin on endothelial cell metabolism
Recently, endothelial cell metabolism (such as glucose, fatty acid, lipid, etc.) has been shown to be critical for maintaining metabolic health. In 1996, Sasson et al. (1996) showed that metformin (1-5 mM) regulates hexose transport in both bovine endothelial cells and smooth muscle cells. Glucose-starvation induces ER stress in mouse microvascular endothelial cells, after treatment with metformin (50 μM and 2 mM), glucose-starvation induced ER stress, was revered. This pharmacological action is exerted through an AMPK-independent mechanism (Samuel et al., 2017) .
Metformin on other kinases and transcriptional factors
LKB1 is one of the upstream kinase of AMPK. Metformin (1 mM) increased the LKB1 phosphorylation at Ser428 and its subsequent nuclear export into the cytosols, and increases AMPK/LKB1 association in ECs (Xie, Dong, Scholz, Neumann, & Zou, 2008) . In addition, Metformin has been shown to influence other kinase activity. For example, Metformin (500 μM) protects against free fatty acid (palmitate) induced endothelial apoptosis and dysfunction, partially by reducing p38 MAPK phosphorylation. This inhibitory effects of metformin on p38 is AMPKdependent, since AMPK inhibition by compound C reverses the p38 inhibiting effects of metformin (Eriksson & Nystrom, 2014) . Metformin (1 mM) also inhibits basal as well as VEGF-induced phosphorylation of ERK 1/2 in an AMPK-dependent manner (Dallaglio et al., 2014) .
Metformin also modulate gene expression via affecting multiple transcriptional factors, such as PPARδ, carbohydrate response element-binding protein (ChREBP), forkhead box O1 (FOXO1), p53, and NF-kB (Hattori et al., 2006) . Specifically, PPARδ is critical for metformin mediated protective effects against ER stress, oxidative stress, and high fat-diet induced endothelial dysfunction (Cheang et al., 2014) . In endothelial cells, Metformin (1-2 mM) also decreases high glucose-induced upregulation of TXNIP by reducing the nuclear transport of ChREBP and FOXO1, and their binding to TXNIP promoter. This effect was reversed by AMPK inhibitor compound C, indicating that metformin impacts ChREBP and FOXO1 in an AMPK-dependent manner (Li et al., 2015) . Metformin (2-10 mM) also dose-dependently inhibits TNFα induced NF-kB (p65 and p50 subunit) activation in HUVECs, which was reversed by AMPK siRNA, indicating an AMPK-dependent anti-inflammatory effects (Hattori et al., 2006) . In addition, Metformin (50 μM) modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1 (Arunachalam et al., 2014) , thereby reducing FOXO1) and p53 acetylation, and decreasing high glucose-induced premature senescence in endothelial cells.
Conclusions and future directions
Hyperglycaemia has deleterious effects on the cardiovascular system mostly the vascular system where it is the cause of microvascular disease and is strongly associated with the occurrence of macrovascular disease. The deleterious biochemical mechanisms of hyperglycaemia are not completely understood at a molecular level but they are probably related to the phenomenon of insulin resistance. Metformin improves insulin resistance and therefore has an anti-hyperglycaemic and insulin-lowering action in patients with Type 2 diabetes. Metformin also has additional actions in the same way as the lipid lowering statins have favourable pleiotropic, anti-inflammatory and anti-oxidative effects on the vasculature beyond their lipid lowering actions. The main effect of metformin is on ED where the integrity of the endothelium is a critical and long-term determinant of vascular health and thus of the occurrence of CVD. We have reviewed the causes of ED and outlined the effects of metformin to improve or to prevent deterioration of ED which potentially leads to reduced CVD in patients with Type 2 diabetes and potentially other settings in which the use of metformin is being proposed. Metformin has a very simple chemical structure. The dose of metformin is relatively high and to some extent its actions might be considered alongside that of nutrients. The simple structure means that it is unlikely that it will be possible to develop new agents with similar or better properties and mechanisms of action so the future relies on fully exploiting the pharmacokinetics, pharmacodynamics and therapeutic targeting to achieve the full therapeutic potential of metformin. This approach has recently been demonstrated by the description of the delayed release metformin product which acts in the distal gut and reveals a gut hormone-dependent anti-hyperglycaemic action of metformin Several important classes of drugs for the treatment of hyperglycaemia have shown in large scale use to display serious unwanted effects such as the bone fractures and heart failure associated with glitazones and the recent signs of the occurrence of amputations of digits associated with the use of some SGLT2 inhibitors (S. Lee, 2017; Wu, Ding, Tanaka, & Zhang, 2014 ). There does not appear to be a hidden unwanted effects profile for, metformin so it has the potential to provide a really effective and safe future in the treatment of hyperglycaemia and especially for its favourable CVD effects including beneficial effects on ED.
